Prostate Cell News Volume 2.31 | Aug 26 2011

Pim1 Kinase Is Required to Maintain Tumorigenicity in MYC-Expressing Prostate Cancer Cells
Researchers examine the molecular consequences of Pim1 and MYC overexpression in the prostate as well as the effects of depleting Pim1 in prostate carcinoma cells with high levels of MYC. [Oncogene]

LABORATORY RESEARCH

Prostate Cancer Increases Hyaluronan (HA) in Surrounding Nonmalignant Stroma and this Response Is Associated with Tumor Growth and an Unfavorable Outcome
The objective of this study was to investigate whether the presence of a tumor increases HA levels in surrounding prostate tissues and whether this extratumoral HA influences tumor growth and outcome. [Am J Pathol]

Persistent Inflammation Leads to Proliferative Neoplasia and Loss of Smooth Muscle Cells in a Prostate Tumor Model
Researchers show that loss of smooth muscle and invasiveness of the tumor are not coupled, with inflammation leading to increased tumor size and a dedifferentiated stroma. [Neoplasia]

LCoR Acts as a Novel Androgen Receptor Corepressor, Inhibits Prostate Cancer Growth and Is Functionally Inactivated by the Src Kinase
Researchers show that the corepressor LCoR acts as an androgen-dependent corepressor that represses human prostate cancer growth in vivo. [J Biol Chem]

Oxidative Stress and Prostate Cancer Progression Are Elicited by Membrane-Type 1 Matrix Metalloproteinase (MT1-MMP)
Researchers demonstrate that MT1-MMP plays a key role in eliciting oxidative stress in prostate cancer cells. [Mol Cancer Res]

17α-Estradiol and Genistein Inhibit High Fat Diet Induced Prostate Gene Expression and Prostate Growth in the Rat
Researchers determined the effects of genistein and 17α-estradiol on the modulation of dietary fat induced prostate 5α-reductase-2 and insulin-like growth factor-1 gene expression, and prostate growth. [J Urol]

Up-Regulation of α_1a and α_1d-Adrenoceptors in the Prostate by Administration of Subtype Selective α₁-Adrenoceptor Antagonist Tamsulosin in Patients with Benign Prostatic Hyperplasia
Researchers examined the change in α₁-adrenoceptor subtype expression in the prostate due to chronic tamsulosin administration in a benign prostatic hyperplasia rat model and in patients. [J Urol]

Synthesis and Evaluation of Poly(Styrene-Co-Maleic Acid) (SMA) Micellar Nanocarriers for the Delivery of Tanespimycin
The micellar drug delivery systems for tanespimycin showed potent activity against DU145 human prostate cancer cells, with an IC₅₀ of 230 nM. [Int J Pharm]

Benefits of Whole Ginger Extract in Prostate Cancer
Researchers show that whole ginger extract exerts significant growth-inhibitory and death-inductory effects in a spectrum of prostate cancer cells. [Br J Nutr]

Expression of the Tumor Antigen T21 Is Up-Regulated in Prostate Cancer and Is Associated with Tumor Stage
The objective of this study was to define the expression pattern of the tumor antigen T21 at the protein level in prostate tissues, prostate cell lines and a panel of normal tissues. [BJU Int]

CLINICAL RESEARCH

A Phase II Study of YM155, A Novel Small-Molecule Suppressor of Survivin, in Castration-Resistant Taxane-Pretreated Prostate Cancer
This study was conducted to determine the activity of YM155 in patients with castration-resistant prostate cancer who received prior taxane therapy. [Ann Oncol]

Suitability of Prostate-Specific Antigen-Detected Localized Prostate Cancers for Focal Therapy: Experience from the ProtecT Study
To identify which patients might benefit from focal ablative techniques, researchers analyzed the surgical specimens of a large sample of population-detected men undergoing radical prostatectomy as part of a randomized clinical trial. [Br J Cancer]

High Incidence of Predominant Gleason Pattern IV Localized Prostate Cancer is Associated With Low Serum Testosterone
Researchers characterized the aggressiveness of prostate cancer by Gleason score and predominant Gleason pattern in relation to preoperative serum testosterone. [J Urol]

FDA Grants Fast Track Designation to Alpharadin for the Treatment of Castration-Resistant Prostate Cancer Patients with Bone Metastases
Algeta ASA announced that Alpharadin (radium-223 chloride) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of castration-resistant (hormone refractory) prostate cancer in patients with bone metastases. [Algeta ASA Press Release]

Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application
Amgen announced that the U.S. Food and Drug Administration will target a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2012 for the supplemental Biologics License Application to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. [Amgen Inc. Press Release]

Creighton Study to Look at Hereditary Prostate Cancer in African Americans
Creighton University’s Hereditary Cancer Center has received a three-year, $731,278 grant from the U.S. Department of Defense to study the role heredity plays in prostate cancer among African Americans. [Creighton University Press Release]

Genomatix Software, USU, and HJF Execute a CRADA: Prostate Cancer Prognostic Marker Discovery by Next Generation Sequencing – Cooperation to Further Progress in Prostate Disease Research
Genomatix Software, the Uniformed Service University of the Health Sciences (USU), and the Henry M. Jackson Foundation (HJF) for the Advancement of Military Medicine, Inc. have entered into a Cooperative Research and Development Agreement (CRADA) to extend their collaborative endeavors in prostate disease research. [Genomatrix Software Press Release]

Christiana Care Health System and Wistar Institute Form a Cancer Research Partnership
Christiana Care Health System’s Helen F. Graham Cancer Center and The Wistar Institute have entered into an historic partnership to collaborate on translational cancer research with the aim of bringing the latest discoveries in cancer research to cancer patients in the community. [Christina Care Health System Press Release]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)              

September 17-20, 2011

Chicago, United States 

NEW National Conference on Biopharmaceuticals & Healthcare

November 4-5, 2011      

Bangalore, India              

NEW Stem Cell Society Singapore Symposium 2011         

November 17-18, 2011 

Singapore, Singapore    

NEW American Association for Cancer Research: Advances in Prostate Cancer Research               

February 6-9, 2012          

Orlando, United States 

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Research and Development Technologist (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Prostate Cancer Scientist (McGill University Health Centre) 

Research Associate – Development (Precision Therapeutics, Inc.) 

Postdoctoral Position – Stem Cells and Immunology (University of Connecticut)  

Postdoctoral Fellow in Prostate Cancer Research (University of Texas Southwestern Medical Center)


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.